This article was originally published in The Gray Sheet
Executive SummarySales reps accounting for at least 50% of Sulzer's U.S. electrophysiology volume have accepted offers as of Oct. 28 to join Guidant's Cardiac Rhythm Management division, satisfying a "key condition" in the Sulzer purchase announced Sept. 21 ("The Gray Sheet" Sept. 28, p. 8). The price of the all-cash deal, pegged between $775 mil. and $850 mil, hinges on the number of reps who join Guidant by closing. Guidant will continue to offer employment to Sulzer reps not yet contacted
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.